Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrolizumab maintenance of remission study in TNF inhibitor-naive ulcerative colitis
2013-004280-31Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Etrolizumab maintenance with Placebo maintenance (2 arms). Primary endpoint: Maintenance of remission at Week 62. Started Jul 2014; status: completed.
02
Drugs
Etrolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2013-004280-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004280-31.